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ABSTRACT 
The endothelium is the thin layer of cells that lines the interior surface of blood 
vessels and is the first site of contact between immune cells and tissues. Therefore, 
alterations at the level of the endothelium are crucial to understand the nature of 
vascular diseases and organ damage. The presence of anti-endothelial cell 
antibodies (AECAs) has been associated with such conditions. However, their 
immunomodulatory and clinical relevance is unclear.  
This work focused on two clinical groups, patients with chronic kidney disease and 
heart- and vein-transplanted patients. In chronic kidney disease patients, some 
biological mechanisms by which AECAs may affect the kidney microvascular 
permeability were explored. In transplanted patients, special emphasis on the 
clinical contribution of these antibodies to monitor graft outcome pre- and post-
transplantation was analyzed. Detection of AECAs using different tissue endothelial 
cells as targets and experimental in vitro assays were utilized to evaluate immune 
interactions of AECAs. 
In patients with end-stage renal disease, AECAs were specifically reactive with 
kidney endothelial cells. In vitro, these antibodies decreased the expression of 
intercellular junction assembly proteins altering endothelial permeability. In heart-
transplanted patients, the presence of autologous AECAs post-transplantation was 
associated with the presence of donor-specific AECAs and early rejection episodes. 
In the context of a first case report of a bioengineered transplanted vein, AECAs 
appeared after nearly a year post-transplantation. 
In summary, AECAs in patients with chronic kidney diseases may be novel 
biomarkers of kidney endothelial dysfunction, and may be used as indicators of 
renal diseases. Additionally, AECAs have important implications in organ 
transplantation regarding the development of techniques for improved donor organ 
selection and monitoring of recipients. Results may also be extended to new 
approaches in tissue engineering.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Förändringar i det innersta cellagret av blodkärl – endotelet - har visat sig ha stor 
betydelse för utveckling inom djurriket. Förändringar är särskilt viktiga i samband 
med uppkomst av många sjukdomar som drabbar våra organ. Förekomst av 
antikroppar riktade mot endotelet (AECAs) har påvisats mot en rad sjukdomar, men 
den exakta betydelsen och mekanismen av AECAs är däremot dåligt känd. 
 
Avhandlingen fokuserar på förekomst av AECA vid njursjukdom, vid 
hjärttransplantation samt vid regenerering av vener använda för att ersätta en icke 
fungerande ven till levern från tarmen hos barn. 
 
Hos njursjuka patienter påvisades AECAs kopplade till förbindelse proteiner i 
kärlväggen. Den föreslagna verkningsmekanismen är att genomsläppligheten av 
äggviteämnen ökar, med skada av njurfunktionen som följd. 
 
Hos hjärttransplanterade patienter medförde förekomst av AECAs riktade mot den 
egna vävnaden att risken för uppkomst av skadliga vävnads antikroppar mot 
givaren (DSA) ökade. Detta kan innebära en ökad risk för både akut och kronisk 
avstötning av hjärtat efter transplantation. 
 
Vid regenerering av ven från ett acellulärt extra cellulärt (ECM) matrix från 
givarblodkärl kunde AECAs riktade mot egen vävnad upptäckas efter ett år, men 
det är osäkert om mängden är av signifikans eftersom materialet är litet och det är 
svårigheter att veta hur stor förändring från kontroll individer som ska anses vara 
signifikant. 
 
Sammanfattningsvis kan AECAs få en potentiell roll som markör vid vissa 
njursjukdomar. Vidare förekomst av AECAs vid hjärttransplantation vara en markör 
för akut eller kronisk avstötning och motiverar därför ytterligare studier. Vid 
regenerering av vävnader och organ – en ny teknik som börjat användas på 
patienter – är det oklart om AECAs innebär en risk för patienten. Ytterligare studier 
är därför motiverat även här. 
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INTRODUCTION 
Cardio Vascular Disease (CVD) is a group of diseases recognized as the number 
one cause of death worldwide. They are categorized within a pathological-
conglomerate that affects primarily the heart and blood vessels. Although, there is 
no precise consensus as to the origin of CVD, several risk factors such as age, 
ethnicity, family history, high cholesterol, obesity, physical inactivity, unhealthy diets, 
diabetes, hypertension, tobacco exposure and immoderate use of alcohol have 
been attributed (1). 
In physiological terms, a vascular network of arteries, veins and capillaries supports 
every organ in the body. Dysfunction of the vascular tree at different levels (e.g. 
macro and/or micro) leads to a chain of inflammatory events and improper blood 
supply resulting in organ damage (2). From this standpoint, a reciprocal relationship 
exists between the vascular health and organ health. 
Vascular dysfunction is a complex process characterized by an imbalance of 
cellular components and vasoactive substances that alter the broad functionality of 
the endothelium. With more knowledge about the nature of the endothelial cells, 
vascular dysfunction is now viewed from a wider perspective, including the constant 
changes of damage/repair that the endothelium undergoes in response to 
biological, chemical and mechanical injuries (2, 3). For instance, an increasing 
number of reports suggest the importance of anti-endothelial cell antibodies 
(AECAs) in endothelial dysfunction, especially in autoimmune and inflammatory 
disorders, as biomarkers of disease activity (4). AECAs have also been regarded as 
important in organ transplantation. In particular, AECAs have been associated with 
allograft rejections of HLA-matched individuals (5, 6). Even though the presence of 
AECAs has been documented in conjunction with such conditions, there are 
controversial opinions and contradictory data about their clinical significance (7, 8). 
One of the fundamental reasons behind these inconsistencies is the lack of reliable 
methods for AECAs detection (8-10). Owing to the heterogeneity of endothelial cells, 
it is important to study the functionality of these antibodies using appropriate 
endothelial targets. In this work, the clinical relevance of AECAs in CKD and heart-
transplanted patients was investigated. AECAs were also explored in the context of 
a bioengineered vein. Selective AECAs were detected by flow cytometry using 
specific endothelial cell targets from the kidney, heart and peripheral endothelial 
progenitor cells. 
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Endothelium 
The endothelium (from the modern Latin endo "within" and the Greek th?l? "nipple", 
which together suggest “deep within our breast”) constitutes the monolayer of cells 
that cover the inner surface of blood vessels and has direct contact with the 
bloodstream. The endothelium consists of approximately 60 trillion endothelial cells 
and has a mass and equivalent surface area of approximately 1kg and more than 
4000m2 respectively (11). Historically, it was conceived as a mere homogeneous 
and inert membrane of cells. This notion changed when electron microscopy studies 
revealed that the endothelium from various organs and different vascular sites within 
the same organ was physically distinct (12). Currently, it is considered an integrated 
organ system because it is actively involved in many physiological processes as a 
driving force controlling homeostasis, permeability selection, vasomotor tone, 
leukocyte trafficking, immunity and angiogenesis (13). Therefore, endothelial cells 
(ECs) are not a simple barrier between blood fluid and underlying tissue. They also 
act as an endocrine and paracrine organ. These fundamental characteristics 
explain the reason why the ECs display remarkable heterogeneity in space, time, 
structure, health and disease.  
Endothelial heterogeneity 
Endothelial cell heterogeneity is the core of the endothelial system. Although the 
precise properties of how ECs acquire heterogeneity are unknown, it is believed that 
the dynamic and adaptive behaviour of ECs are determined by interactions of the 
endothelium with the surrounding tissue environment, soluble factors, and via cell–
cell interactions (14). However, a genetic predisposition as phenotypic endothelial 
heterogeneity has also been ascribed (15). Evolutionary approaches also seek to 
explain the endothelial discrepancy. The endothelium throughout the body must 
provide a broad menu of functions that are adapted to the diverse needs of the 
underlying tissues. Site-specific differences in function will, in turn, be reflected by 
structural and molecular heterogeneity. Thus, ECs must adapt to different 
environments simply to survive. For example, ECs in the vasa recta of the inner 
medulla of the kidney are exposed to profoundly low levels of oxygen, in addition to 
high potassium (K+) levels (16). These unique adaptations to “harsh” 
microenvironments render them phenotypically distinct from other endothelial types. 
Endothelial cells may be classified by size, thickness, shape, and nuclear 
orientation. Depending on where they are located the morphology changes 
according to their functional need (17). Usually, a uniform or continuous layer of 
cells represents the endothelium of large vessels where adjacent ECs are held 
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together by tight junctions to limit fluid exchange between the plasma and the tissue 
fluid. Clear examples are found in most of vascular arteries, veins and capillaries 
from the central nervous system, dermis, skeletal tissue, cardiac smooth muscle and 
ovary tissues. ECs may also be lined as discontinuous layers to allow cellular 
trafficking between intercellular gaps such as in liver, spleen and bone marrow 
sinusoids. Other intercellular gaps common in ECs include the presence of 
fenestrae, as found in the intestinal mucosa and the renal glomeruli, which facilitates 
the selective permeability required for efficient absorption, secretion, and filtering. 
The only difference between discontinuous and fenestrated ECs is the diameter of 
the pore and the presence or absence of a diaphragm, Image 1 (18, 19).  
 
 
Image 1. Disposition of endothelial cell layers (Columbia University, Kung-ming, 2005) 
 
Other functional ECs properties are also regulated by the expression of receptor 
proteins on the surface of the ECs membrane (20). The mechanisms on how ECs 
control this “opening and closing” of intercellular junctions are not well understood. 
It is accepted that trans-membrane adhesive molecules (gap junctions, tight 
junctions, adherens junctions and desmosomes) are linked to a network of 
cytoplasmic/cytoskeletal proteins, which work in a coordinated fashion to control 
endothelial permeability (21-23). When circulating inflammatory agents are present, 
this permeability increases by binding ECs receptors and generating intracellular 
signals, which in turn cause cytoskeletal reorganization and opening of inter-
endothelial cell gaps (24). 
Endothelial progenitor cells (EPCs) 
Despite initial research focused on the endothelial cells of vascular tissues, more 
recent studies on endothelial damage suggest the existence of a subpopulation of 
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circulating vascular repair cells such as EPCs. Their number correlates inversely 
with the degree of disease suggesting that EPCs may serve as a surrogate 
biomarker of vascular function and cardiovascular risk (25-27).  
Most publications define EPCs as endothelial cells, which express hematopoietic 
cell markers such as VEGFR+, CD34+, CD133+ or Tie-2. These cells may have 
multiple sources of origin such as hemangioblasts, non-hematopoietic 
mesenchymal precursors in bone marrow, monocytes and tissue resident stem cells 
(28-31). Accepted theories suggest that the number of adult EPCs increases in the 
blood in conjunction with the manifestation of vascular emergency where they arrive 
to the site of vascular damage to propagate the formation of a new blood vessel (30-
32). Although these cells have been reported in healthy individuals and different 
diseases and conditions, their mode of action is still not clear.  
The endothelium in diseases 
Extrinsic or intrinsic alterations of the endothelium may result in a dysfunctional state 
affecting the vascular network in a local or systemic fashion. These irregularities 
were previously associated with a limited number of diseases related to 
arteriosclerotic disorders. Recent work suggests an expanded view regarding the 
role of the endothelium. Given that the endothelium is multifunctional and highly 
distributed in space, it is now thought to play an important role in most if not all 
diseases, either as a primary target of pathophysiology or as a victim of collateral 
endothelial cell injury (33).     
 
Antibodies 
Antibodies are a group of globular proteins called immunoglobulins (Ig) produced 
by plasma cells and found in blood, secretions and other fluidic tissues. They are 
formed of many various amino acid sequences and are the most diverse proteins 
known (34). The function of an antibody is to bind to an antigen, which is normally a 
foreign or non-self molecule. This binding capacity is determined by their chemical 
structure conferring them distinctive features of binding versatility, binding 
specificity and biological activity (34, 35). 
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Image 2.  Three-dimensional structure of a typical IgG antibody (Visual Science, 2014) 
 
Generally, antibodies are Y-shaped consisting of two heavy and two light chains 
linked by disulfide bonds and non-covalent interactions (Image 2). In the two arm 
regions (for both, heavy and light chain), they have an antigenic-binding region (Fab 
fragment) that functions as an antigenic binding site. Each chain has a variable 
region at the end of both arms (circle). The rest of the chain is considered as a 
constant region. The tail-region of the heavy chain, which decides the biological 
activity of the antibody, is known as the fragment crystallizable (Fc) region. The Fc 
region defines whether the response against a particular antigen will lead to 
complement-mediated lysis, enhanced phagocytosis, or allergy (36). Because the 
amino acid sequence differs in the arms of various antibody molecules, each 
antibody can bind specifically to one unique antigenic determinant. Thus, the arms 
of an antibody molecule confer the versatility and specificity of responses that a host 
can mount against antigens (37). 
Based on differences in the amino acid sequences in the constant region of the 
heavy chains, there are five major types of antibodies known as IgG, IgM, IgA, IgE 
and IgD (37).  
IgG has a monomeric configuration and is the most common and versatile of all the 
antibodies in the body (around 70-75% in serum). They are the only type of 
antibodies that pass to a fetus through a mother's placenta and are particularly 
important to fight off infections. IgG fix complement (a group of circulating proteins 
of the immune system), promotes neutralization, agglutination, and opsonization of 
the antigen (37).  
Variable 
Regions 
Fc Domain 
Fab Domain 
 Heavy Chains 
Light Chains 
Antigenic 
Binding Sites  
 
 
18
 
IgM is the larger antibody and usually has a pentameric structure. It is found in 
serum (10-15%) and lymph fluid and is the first antibody to appear during an 
immune response. Because of its many antigen-binding sites, IgM can quickly 
clump antigen and efficiently activate complement. IgM acts as one of the main 
receptors on the surface of mature B cells, along with IgD. When IgM is a surface 
receptor, it is in its monomeric form (35, 36). IgM also activates macrophages to 
phagocytize pathogens. 
IgA antibodies (10-15% in serum) are dimers, predominantly present in secretions 
from the lung and intestine as well as mucus, saliva, breast milk and tears. Normally 
IgA does not fix complement, unless aggregated. They protect body surfaces that 
are exposed to outside foreign substances (mucous membranes) (38). 
The monomer IgD constitutes less than 1% in human serum and they have been 
found in tissue lining of the chest and stomach. IgD is an antibody whose function 
remains unknown, even though it is one of the main receptors on mature B cells. As 
B cells mature IgD is replaced by other antibodies. IgD may be a regulator of 
immune responses through its role in antigen internalization (36, 39) 
IgE makes up less than 0.003% of the antibody in serum. IgE is a monomer and 
binds through its Fc part to mast cells or basophils (a type of white blood cells). On 
later exposure to the same antigen, mast cells and basophils bind antigen with 
membrane-bound IgE and trigger allergic reactions. For that reason IgE levels are 
often high in people with allergies (e g. pollen, fungus spores, animal dander, some 
food, medicines and poisons). IgE protects against parasites by releasing mediators 
that attract eosinophils (36, 39).  
Common aspects of Anti-endothelial cell antibodies (AECAs) 
AECAs were first reported in the 1970’s in studies with tissues of kidney biopsies 
and sera of patients with rheumatic diseases and Systemic Lupus Erythematosus 
(SLE) (40, 41).  In addition, they have been reported predominantly in systematic 
autoimmune and vascular disorders such as Rheumatoid Arthritis, Wegner 
Granulomatosis, Kawasaki Disease, Behcet’s Disease, Takayasus Arteritis, 
Microscopic Polyangiitis, SLE and Inflammatory Bowel Diseases (4, 42-46), and their 
presence has been also described in organ transplantation in association to 
rejections and in normal individuals as a set of natural antibodies (47, 48).  
AECAs belong to a heterogenic group of immunoglobulins that covers a large 
spectrum of target antigens that may be constitutively expressed or induced by 
cytokines and adherent molecules on ECs (7). Different isotypes of IgG, IgM and 
IgA have been mostly documented and several studies suggest that AECAs from 
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different sources recognize multiple types of ECs target molecules (7, 46, 47, 49, 
50), see Table 1. These isotypes bind mainly through the F(ab)2 portion of the Ig and 
might be tissue-specific and correlated to the disease origin (51-53). 
Table 1. Antigenic specificities of AECAs in healthy individuals and different 
diseases. 
 
Condition 
 
 
Target antigen 
 
Pathogenicity 
Normal Individuals ?-Actin, ?-Tubulin, Vimentin 
Prolyl-4-hydroxylase ?-
Glyceraldehyde-3-phosphate-
deshydrogenase  
?-Enolase  
 
Systemic lupus DNA-DNA-histone 
 
 
Erythematosus Ribosomal P protein PO 
Ribosomal protein L6 ? 
Elongation factor 1-alpha ? 
Adenylyl cyclase-associated protein 
Profilin 2 ? 
Plasminogen activator inhibitor 
Fibronectin ? 
Heparan sulfate ? 
?2-glycoprotein I 
Heat-shock protein 60 (Hsp 60) 
Heat-shock protein 70 (Hsp 70)  
Fibronectin leucine-rich transmembrane 
protein 2 (FLRT2)  
 
 
 
 
 
 
 
 
 
 
Apoptosis 
 
Complement dependent 
cytotoxicity 
Mixed connective tissue 
disease 
Voltage-dependent anion-selective 
channel 1 (VDAC-1) 
 
Systemic sclerosis Topoisomerase I 
Centromere protein B (CENP-B) 
 
 
Vasculitis Proteinase 3 ? 
Myeloperoxidase ? 
Peroxiredoxin 2 
Adenosine triphosphate (ATP) synthase 
 
 
Cytokine secretion 
Intracellular acidification 
Microscopic polyangiitis Human lysosomal-associated membrane 
protein 2 
 
Behçet's disease Alpha-enolase ? 
C-terminus of Ral-binding protein 1 
(RLIP76) 
 
Apoptosis 
Kawasaki disease Tropomyosin 
T-plastin 
 
Thrombotic thrombocytopenic
purpura 
 
 
Glycoprotein CD36 
 
Heparin-induced  
thrombocytopenia 
Platelet factor 4 (PF4) 
Heparin sulfate 
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Whether AECAs exert a pathophysiological effect is poorly understood. 
Investigations have shown that in pathological conditions by concurrent 
inflammation of different types of blood vessels, AECAs recognize a large panel of 
antigens on ECs (47). They mediate their effects via increasing leukocyte 
adhesiveness, apoptosis, cytotoxicity, coagulation, and thrombosis (54-57). This is 
in contrast to the case of healthy individuals in which AECAs react with a limited 
number of self-antigens (47, 58).     
Observations in patients with Takayasus Arteritis (chronic inflammation of the large 
blood vessels that distribute blood from the heart, including the aorta and its main 
branches) have shown that AECAs may cause vascular dysfunction by inducing 
expression of adhesion molecules E-selectine, VCAM-1 on aortic endothelial cells as 
well as production of interleukins IL-4, -6 and -8, and apoptosis (59). However, these 
AECAs have also been detected on other endothelial targets, where they may bind 
and activate macrovascular ECs from umbilical cord and not microvascular 
immortalized ECs from bone marrow. This occurs through elevation of adhesion 
molecule expression associated with NF-kB activation and adhesion of monocytes, 
and may therefore play a pathogenic role in the development of vasculopathies (60).  
Other instances of the etiological role of AECAs in SLE and Wegner Granulomatosis 
patients include up-regulation of proinflammatory cytokines and chemokines with 
leukocytic accumulation and display of proadhesive endothelial proteins (53). 
Different data also suggest that AECAs might mediate endothelial changes through 
complement fixation or cytotoxic effector cells causing ECs lysis (61). 
 
AECAs in Chronic Kidney Disease 
Chronic kidney disease (CKD) describes the gradual loss of kidney function over a 
period of time. The primary function of the kidneys involves the regulation of blood 
composition by removing wastes from the body (e.g. urea, ammonia, drugs, toxic 
substances), keeping constant acid/base concentrations, and regulating calcium 
levels and water volume (62, 63). Disruption of this integrity is thought to be result of 
ongoing endothelial damage in the capillary system (blood-urine interface, 
glomeruli) of the renal medulla, accompanied by small vessel disappearance or 
reduced blood flow leading to microalbuminuria, a clinical sign of “kidney leakage” 
(64-66). However, the molecular mechanisms by which the kidney loses the 
microvascular capacity for controlling the glomerular permeability are unclear.  
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During the course of CKD, a large proportion of patients develop cardiovascular 
disease (67). Although diverse factors are implicated, it has been considered that 
endothelial dysfunction represents a key modulator mechanism by which the 
endothelium of the vascular system is perturbed accompanying the progressive 
deterioration of the renal function (68, 69). 
In previous publications about endothelial cell dysfunction, a high presence of 
AECAs in patients with CKD has been reported. In a study model, using patients 
with Wegner Granulomatosis disease (a vascular disorder with inflammation of the 
respiratory tract and necrotizing of small blood vessels resulting in pulmonary 
hemorrhage and renal failure), it was found that AECAs were associated with tissue 
specific endothelial cells from kidney, nose and lung but not umbilical cord (70). 
These results suggest that AECAs in Wegner Granulomatosis appear to have a 
correlation with organ distribution. In addition, important observations regarding the 
possible role of stimulated ECs with inflammatory cytokines IFN-? ? and TNF-??, 
show alterations in the accessibility of ECs surface molecules, resulting in a 
significant decrease of AECAs binding (70, 71). 
Patients with end-stage of renal disease (ESRD) are prone to develop severe CVD. 
This group of patients represents the worst-case scenario of kidney damage and 
these patients are good candidates for studying the mechanisms of localized 
microvascular dysfunction and the poorly understood way that tissue-specific 
AECAs affect the renal microvascular circulation. It is therefore clinically relevant to 
explore the functional effects of AECAs as a mediator of increased ECs permeability 
on a controlled group of kidney ECs.  
 
AECAs in Transplantation 
In organ transplantation it is accepted that the presence of antibodies to human 
leucocyte antigens (HLA) are detrimental to patient survival and function. 
Furthermore, the presence of HLA is known to increase the probability of rejection of 
the transplanted organ (72).  
HLA - or the Major Histocompatibility Complex (MHC) - is encoded by a group of 
genes on chromosome 6 giving rise to most of the polymorphic proteins residing on 
the surface of almost every cell in the body (73). There are two major types of HLA 
antigens, HLA class-I (HLA-A, -B and -C) and HLA class-II (HLA-DR, -DQ and -DP). 
The prime function of these antigens is to serve as recognition molecules in the 
initiation of an immune response where they present peptides from foreign 
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substances to effector cells. These peptides are responsible for driving both the 
cellular and the humoral immunity (74). 
Traditional tests of immune histocompatibility between donors and recipients 
include HLA typing (to match genetically similar individuals), blood group (ABO) 
and a lymphocytic crossmatch test (75). Patient serum is tested for their reactivity 
with donor T- and/or B-lymphocytes, which is detected by the presence of Donor 
Specific anti-HLA Antibodies (DSA). In patients awaiting a kidney transplant, the 
presence of DSA is strongly associated with acute Antibody Mediated Rejection 
(AMR) (76, 77). Therefore, the immune histocompatibility match plays an important 
role in the success of kidney transplantation. For liver and pancreas transplants, an 
exact match is less influential. Heart and lung patients generally profit from 
matching as well, although urgency is the major criterion for allocating these organs 
(78). 
Naturally occurring HLA antibodies may be present in some individuals (79). 
Indeed, natural anti-HLA-A2 and anti-B8 have been identified by in some patients 
where they belong to the IgM class (79-82). Apart from naturally occurring HLA 
antibodies, these antibodies may arise in individuals as a result of pregnancy, blood 
transfusion, or previous transplantation (83, 84).  
However, knowing that pre-transplant HLA crossmatches are performed to identify 
patients at risk of losing their grafts and post-transplant immunosuppressive 
regimens are combined as part of the management to reduce rejections; in the 
absence of HLA antibodies or even in identical HLA-matches, rejections are still 
known to occur (85, 86). This suggests that other antigenic systems different to the 
traditional lymphocytic HLA or non-HLA are implicit in the etiology of organ rejection 
(5, 6, 87). 
Since the endothelium of a donor organ is the first tissue that the recipient's blood 
encounters, the ECs are the most immediate targets for the host's immune system 
during allograft rejection. This is supported by the fact that ECs have been 
considered as important carriers of non-HLA antigens (88, 89). Investigations on 
organ injury and manifestations of rejections have suggested that AECAs, grouped 
as part of the non-HLA antibodies, are clinically important (48, 90, 91). AECAs do 
not react with lymphocytes; therefore, they are not detected by conventional 
crossmatch tests. Furthermore, currently their presence is not investigated in routine 
clinical procedure due to the lack of reproducible methods of detection. 
Nonetheless, characterization of some putative antigens recognized by AECAs has 
been reported in transplantation, Table 2, reviewed by Sumitran-Holgersson in (5). 
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Table 2. AECAs associated with graft rejection 
Endothelial specificity Type of 
transplantation 
Type of 
rejection 
 
Vimetin, Desmin 
 
Heart 
 
AR 
 
Endothelial specific antibodies 
against a 100 kD antigen 
 
Kidney 
 
HAR, AR 
 
Endothelial-monocyte specific 
antibodies (HMA-1 and HMA-2) 
 
 
 
Kidney 
 
HAR, AR 
 
MICA 
 
Kidney 
 
EGL, AR 
 
Angiotensin II type-1 Receptor 
 
Kidney 
 
VR 
 
?-Galactosidase 
 
Xeno 
 
HAR 
AR=Acute rejections; HAR=Hyperacute rejections; EGL=Early graft loss; VR=Vascular rejection 
MICA= MHC class I–related chain A 
 
Mechanisms by which AECAs may cause endothelial dysfunction 
Induction of proinflammatory phenotypes  
AECAs may induce an EC phenotype that will support leukocyte extravasation 
through upregulated expression of adhesion molecules, e.g. E- and P-selectin 
(CD62E/P), VCAM-1 (CD106) and ICAM-1 (CD54), inflammatory cytokines (IL-1?, 
TNF-?) and chemokines such as IL-8 (92). 
By inducing expression of co-stimulatory molecules (CD86), antibodies may 
facilitate direct T-lymphocyte activation by the endothelium (93). Further, AECAs 
have been shown to facilitate migration of human NK cells across porcine 
endothelium (94). 
Augmentation of cellular immunity  
Transforming growth factor beta (TGF-?) is a cytokine constitutively produced by 
several endothelial cells and is well known for suppressing T cell proliferation. It has 
been reported that binding of AECAs to Liver ECs in liver transplant patients down-
regulates TGF-? levels, thereby enhancing cellular immune responses (93). Thus, 
increased T cell proliferation during liver allograft rejections could be a result of 
combined antigen presentation by liver ECs with decreased TGF-? levels. It can be 
speculated that AECA binding to an antigen expressed on the ECs of the 
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transplanted liver allograft may facilitate uptake of the antigen by antigen-presenting 
cells and presentation to allo-specific host T cells. 
Induction of Prothrombotic phenotypes  
In kidney transplant patients, MICA antibody-containing sera from patients may 
activate kidney ECs and induce a pro-thrombotic phenotype leading to vascular 
thrombosis and graft loss (95). Similarly, induced non-?-Galactosidade antibodies 
from baboons transplanted with porcine kidneys have been shown to induce tissue 
factor expression on pig ECs (96).  
Induction of Morphological changes  
In liver disease patients, it is reported that AECA binding to liver ECs can capillarize 
the sinusoidal endothelial cells by inducing production of a basement membrane, 
loss of fenestrae and formation of tight junctions (97). The ensuing consequences 
may result in the development of hepatocellular failure. Thus, morphological 
transformation of liver EC to vascular-type endothelial cells in patients with AECAs 
may have important clinical consequences. Capillarization of liver ECs in liver 
allografts have been reported during rejections, thus AECAs to liver ECs may 
mediate liver allograft rejections (98). Furthermore, AECAs may induce cell shape 
changes, motility, cytoskeletal redistribution and EC permeability. The clinical 
consequences of these changes are less well-known.  
Apoptosis  
AECAs have been reported to exert pro-apoptotic activity on ECs. It has been has 
shown that AECAs from pre-transplant kidney recipients may induce arterial EC 
death in vitro through apoptosis (91). However, whether AECAs promote or not 
endothelial apoptosis has to be further studied. 
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AIMS  
The general aims of this work were: 
1) To study the frequency and presence of AECA in patients with CKD and some 
transplanted patients. 
2) To study the clinical relevance of these antibodies in endothelial dysfunction. 
 
 
The specific aims of the study were: 
 - To explore mechanisms of endothelial dysfunction in CKD patients caused by 
AECAs reactive to renal microvascular endothelial cells (Paper I) 
 - To study the relationship between AECAs and early rejection events in heart-
transplanted patients (Paper II and III) 
 - To screen for the presence of AECAs in a patient transplanted with a 
bioengineered vein (Paper IV). 
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METHODOLOGICAL CONSIDERATIONS 
 
 
             Diagram 1. Methodological overview to study AECAs 
 
 
This section outlines how AECAs were studied (Diagram 1) and other general 
methodological considerations. For more details, please refer to the respective 
paper. 
 
 
 
Paper IV 
Bioengineered 
Transplanted Vein 
Paper II and III 
Heart-transplanted 
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28
 
Patients 
Paper I   
Forty-five ESRD patients at the Karolinska University Hospital, Huddinge, Stockholm 
were included. The patients were enrolled at a time point close to the start of renal 
replacement therapy with a median glomerular filtration rate (GFR) of 5.7. The 
causes of CKD were: chronic glomerulonephritis in 10 patients, diabetic 
nephropathy in 14 patients, polycystic kidney disease in 4 patients, nephrosclerosis 
in 2 patients, and unknown etiologies in 15 patients. The presence of clinical CVD 
was defined by medical history, clinical symptoms, and/or findings of cardiac, 
cerebrovascular (stroke), and/or peripheral vascular disease. Other clinical 
characteristics are shown in Table 1 of this study. 
Paper II   
A 42-year-old male patient with ankylosing spondylitis (a form of arthritis causing 
chronic inflammation of the spine) and ulcerative colitis in remission was diagnosed 
with giant cell myocarditis (GCM - a rare cardiovascular disease where patients 
develop abnormal heartbeats, chest pain and even heart failure) at the Sahlgrenska 
University Hospital. According to endomyocardial biopsies (EMBs), the GCM 
regressed on cyclosporine, azathioprine and corticosteroids. He was stable for four 
years, but deteriorated thereafter with advanced heart failure.  
Paper III   
Twenty-five consecutive heart recipients were selected from the Sahlgrenska 
Transplant Institute´s Biobank for the isolation of PBMCs. Eleven patients were 
excluded due to lack of donor PBMCs or pre-transplant serum from the recipients 
leaving fourteen patients included in the study. The immunosuppressive regimen 
protocol consisted of mycophenolate mofetil, steroids and tacrolimus or 
cyclosporine (see Table 1 of this paper). 
Paper IV   
A 10-year-old girl developed thrombocytopenia (disorder with abnormally low 
amount of platelets) and splenomegaly (enlargement of the spleen) and was 
diagnosed with idiopathic thrombocytopenic purpura (ITP). Her case was handled 
for several years at a local hospital. When the patient was 9 years old she was 
reassessed and referred to the Sahlgrenska University Hospital. Oesophageal 
varicose veins and splenomegaly were confirmed. The patient’s international 
normalized ratio (INR) was slightly elevated (1.4), concentrations of protein S and 
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protein C were normal, and activated protein C resistance was excluded. The 
patient was given ?-blockers to reduce portal hypertension. 
Serum Samples 
In the present studies, AECAs were obtained from serum samples. Peripheral blood 
from the patients were collected, centrifuged, aliquoted and stored at -80°C for 
further experiments. In patients that underwent a transplant (Papers II, III and IV) the 
same procedure was repeated. Blood samples were collected before and after 
surgery. Before surgery, samples were taken between five months to one month 
prior to and on the day of intervention. After transplantation, samples were taken at 
different time intervals of one and two weeks during immediate recovery and 
subsequently at one, three, and six months into recovery. Only samples from the 
patient in Paper IV were taken during more than one year. Blood from healthy male 
individuals (controls) were also included for generation of serum. 
Biopsies 
Paper I  
Kidney biopsies from ESRD patients and normal individuals were used for 
immunohistochemical (IHC) staining of cell junction proteins. 
Paper II and III  
Cardiac biopsies from heart-transplanted patients were included for 
immunohistochemistry (IHC) in papers II and III and immunofluorescence (IF) 
staining of antibody deposition and rejection markers in paper III. 
Paper IV  
Biopsy samples from the graft were taken for immunobiological assessment by IHC 
and IF before (native tissue), during (decellularization) and after (recellularization) 
the creation of the new vein. 
Isolation of PBMCs from donors and patients (Paper II, III and IV) 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from blood of 16 
deceased heart organ donors and two cadaveric vein graft donor via the density 
gradient media, Lymphoprep ™ (Axis-Shield PoC AS, Oslo, Norway). A lymphoprep-
blood suspension was prepared and centrifuged at 1500 rpm for 20 min at room 
temperature. After centrifugation, a white interface layer (mononuclear cells) was 
collected, washed and frozen in liquid N2 for subsequent use. The same procedure 
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was used for the isolation of PBMCs from the patients at the same time intervals as 
indicated above for the isolation of sera. 
Immunomagnetic cell separation (Paper II, III and IV) 
Immunomagnetic cell separation is a technique based on the attachment of small 
magnetic particles to cells via antibodies or lectins. When a mixed population of 
cells in suspension is placed in a magnetic field, those cells that have magnetic 
beads attached will be attracted to the magnet and may thus be separated from the 
unlabeled cells (99). This method is quick, easy to perform and generally gives a 
good yield of cell isolation.  It should be noted, however, that only positive and 
negative cell populations can be separated. However, the limitation is that selection 
cannot be made based on level/density of expression of various molecules. 
Moreover, only cell surface molecules can be used as markers for magnetic 
separation of live cells and not by other means such as the expression of green 
fluorescent protein in transfected cells (100, 101). 
Papers II, III and IV  
Immunomagnetic cell separation was utilized in studies II, III and IV for the isolation 
of EPC/Tie-2 positive cells from blood using a Dynal™ magnet that is suitable for 
working with large samples and where the degree of cell purity is not a crucial factor 
(since the cells were not intended for cultivation). In study IV, a more robust 
separation magnet using magnetic columns from MACS® was used for the isolation 
of CD133 positive cells from bone marrow and subsequently, cell cultivation, 
differentiation and repopulation of a new bioengineered-vein graft. 
Isolation and cultivation of endothelial cell lines (Paper I, III and IV) 
Paper I  
Human kidney endothelial cells (HKECs) were isolated from a donated kidney, 
considered non-suitable for transplantation, using an enzymatic method described 
by Daneker, GW. et al. 1998 (102). The cells were cultured in MCDB 131 endothelial 
medium, supplemented with growth factors EGM-2 single-quots (Lonza, 
Clonetics®). To maintain fenestrae in HKEC, vascular endothelial growth factor 
(VEGF) was also added and scanning electron microscopy was used to detect 
endothelial fenestrae. Capillary formation in Matrigel® and morphological 
characterization of HKECs were also performed by optical microscopy. Other ECs 
lines used in this study were human ECs from umbilical vein (HUVECs), artery 
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(HAECs) and lung (HLECs) which were purchased from Clonetics® and cultured in 
same conditions as HKECs in MCDB 131 medium. 
Paper III    
Human Cardiac Microvascular Endothelial Cells (HCMECs, Clonetics®) were 
included in this study as base-line cells. The procedure for cell culturing was the 
same as the mentioned with HKECs. 
Paper IV  
Autologous ECs from the bone marrow of the patient were isolated using CD133-
coated mini MACS beads, following manufacture’s instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). To differentiate the endothelial lineage, CD133 cells 
were cultured with MCDB 131 specifically enriched endothelial growth medium. 
CD133 positive cells, smooth muscle cells were also isolated from the same bone 
marrow. The cells were grown and differentiated in a commercially available 
medium for smooth muscle cells (Cascade Biologics medium 231 plus growth 
factors and differentiation supplements, Invitrogen Corporation Portland, USA).  
Isolation of circulating EPCs (Paper II, III and IV) 
Papers II, III and IV   
In these studies, the patients underwent either a heart transplant (Papers II and III) 
or a bioengineered-vein transplant (Paper IV). In parallel to the standard assays 
performed in clinical routine to detect the degree of compatibility between a donor 
and a recipient (HLA-typing) at Sahlgrenska Hospital, a recently introduced 
endothelial precursor cell crossmatch test (EPC-XM, XM-ONE® AbSorber AB, 
Stockholm, Sweden) was also performed. These additional tests were carried out in 
order to assess AECAs in a clinical setting. 
PBMCs isolated from donors and patients were thawed and washed with RPMI 
medium. Cell viability was examined using optical microscopy with trypan blue 
staining. The cells were then incubated for 30 min with immunomagnetic nanobeads 
coated with the anti-Tie-2 antibody. Finally, the cells were then placed in a Dynal™ 
magnet for 10 min at room temperature. Tie-2 negative cells not adhering to the 
magnet were pipetted and transferred to another tube. The remaining Tie-2+ 
positive cells (EPCs) were recovered by removing the tubes from the magnet and 
resuspending the cells in PBS. After each separation, aliquots of cells were set 
aside for incubation with pre and post transplantation serum samples. 
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Flow cytometry (Paper I - IV) 
Flow cytometry is used for the analysis and sorting of a mixed population of cells or 
particles in suspension that are labeled with particular fluorochromes. By observing 
scattered light from the interaction between labeled cells and the 
laser/flourochrome, it is possible to measure multiple parameters simultaneously 
(e.g. size, granularity, cell cycle, debris, cell death and expression of proteins) on 
each cell. However, since it requires a suspension of single cells or other particles, 
with minimum clumps and debris, the tissue architecture and any information about 
the spatial relationship between different cells are lost when single cells or nuclei 
are prepared (103). Flow cytometry was particularly useful in these experiments as it 
offered a rapid quantitative method for phenotyping ECs and sera samples. 
Endothelial phenotyping (Paper I) 
Isolated ECs from a kidney were phenotyped by flow cytometry with a panel of 
different fluorescent markers to detect endothelial cell identities. 
Screening of sera samples for detection of AECA (Paper I - IV) 
Stimulation of ECs with cytokines in culture induces changes in ECs functions. A set 
of HKECs/HUVECs, unstimulated and stimulated with IFN-? and TNF-? (16 h), 
were used for the screening of AECAs in sera of 45 ESRD patients and 20 healthy 
controls (Paper I). Sera from healthy non-transfused blood group AB men known not 
to have any antibodies served as negative controls. A pool of sera from patients who 
had formed alloantibodies as a result of multiple blood transfusions or organ 
transplantations was used as a positive control. For the assay, HKECs cells were 
incubated with patient’s serum for 1h and then washed with PBS. Fluoresceinated 
goat anti-human IgG and IgM antibodies were then added and incubated. After a 
washing step, the cells were resuspended in PBS and immediately analyzed by flow 
cytometry. Fluorescence signals from 10,000 cells were counted, and the 
percentage of FITC-positive cells was recorded. A shift in the mean fluorescence of 
20 channels in the test sample indicated the presence of AECAs when compared 
with control samples (104). All sera giving positive reactions were further diluted to 
determine titers of AECAs. 
In papers II and III cardiac microvascular ECs were used, and in papers II, III, and 
IV a subpopulation of peripheral EPC/Tie-2 positive cells was isolated using the 
novel EPC-XM kit. EPCs share tissue endothelial characteristics (105) and one of the 
advantages of this EPC-XM method is that it is possible to perform a lymphocyte 
crossmatch test simultaneously. Donor and autologous PBMCs were used for the 
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assays. Donors’ Tie- 2+ cells were distributed in tubes and incubated with serum 
from their respective recipients and stained with anti-IgG and anti-IgM (FITC), anti-
CD3 PE (T cells) and anti-CD19 PerCP (B cells) fluorescent secondary antibodies. 
The samples were run on Becton Dickinson flow cytometer (FACSorter, Becton 
Dickinson, USA) using CELLQUEST PRO analysis software (Paper II and III) and a 
Guava Millipore flow cytometer (Paper IV). Negative and positive control sera were 
included and fluorescence signals of 7000 cells were counted. Positive and 
negative donor-AECAs test values were established for each immunoglobulin 
isotype following parameters from a kidney EPC-XM multicenter study (106) and 
positive lymphocyte crossmatch tests according to a protocol developed by Alheim, 
M. et al. 2010 (107). Autologous IgM AECA values were determined by testing 
AECAs in a set of 20 healthy individuals matched in age and sex using the EPC-XM. 
Shifts in the mean fluorescence channel of more than 52 channels, in the test 
sample as compared to the negative control, were considered as positive. 
Standard HLA typing and screening for HLA-panel reactive antibodies (PRA) of 
patient and donor samples were assessed by personnel from the Transfusion and 
Medicine Department at Sahlgrenska University Hospital, using Luminex, flow 
cytometry and complement-dependent cytotoxicity assays (CDC). Detection of 
donor specific anti-HLA antibodies (DSA) by flow cytometry and CDC crossmatch 
tests was also included.  
Isolation of IgG fractions from AECAs in ESRD patients (Paper I) 
When accurate concentrations of antibody are required, purified antibody fractions 
must be used (108). It is known that the multifunctional IgG is the most abundant in 
human serum (35).  
To assess the concentration and reactivity of AECAs on HKECs, purified IgG 
fractions were isolated by immunoprecipitation of pooled sera from ESRD patients 
with (positive) and without (negative) AECA, using goat anti-human IgG (Fc-chain 
specific) agarose beads 127 (Sigma-Aldrich Sweden, Stockholm, Sweden). The 
concentration of IgG was then determined by the standard Mancini method. Normal 
IgG (11 mg/ml, ChromPure Human IgG) was also used in the tests as a control 
sample.  
Western blot (Paper I) 
The western blot or immunoblotting is a technique used for separation and detection 
of individual proteins in a protein mixture (e.g. a cell or tissue lysates, fluids). The 
protein mixture sample is applied to a gel electrophoresis in a carrier matrix (SDS-
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PAGE, native PAGE, isoelectric focusing, 2D gel electrophoresis, etc.) to sort the 
proteins by size, charge and/or conformation in individual protein bands. The 
separated protein bands are then transferred to a carrier membrane (e.g. 
nitrocellulose, nylon or polyvinylidene difluoride PVDF) where they adhere to the 
membrane in the same pattern as they have been separated due to interactions of 
charges. Finally, this immunoblot is then accessible for antibody binding detection 
(109). The advantages of this technique are that it can determine the size of the 
target protein, it is possible to semi-quantify the protein of interest by running an 
internal quantity standard in parallel with the samples in the gel and different 
samples can be compared simultaneously. The main drawbacks are that it is time-
consuming and has a high demand in terms of optimizing the experimental 
conditions (i.e. protein isolation, buffers, type of separation, gel concentration, etc.). 
A western blot analysis was performed in Study I to check phosphorylation of ECs 
adherens proteins in kidney ECs after stimulation with different IgG fractions.
The presence of tyrosine phosphorylation of VE-cadherin, a cell-cell adherence 
junction protein, has been reported in conjunction with increased ECs permeability 
(110, 111). Cell lysates of stimulated HKECs with IgG from AECA-positive, AECA-
negative and normal individuals were prepared as described by Sumitran et al, 
1999 (112) and immunoblotted with anti-phospho VE-cadherin using standard SDS-
PAGE and Western blot analysis. 
Measurement of endothelial cell barrier function (Paper I) 
In culture, ECs grow attached one to each other in monolayers creating a mesh-like 
structure with certain electrical resistance.  Under experimental conditions, (e.g., 
when influenced by external stimulus), the functionality of this resistance is 
measurable and provides explanatory information about cellular disturbances (113). 
This approach was employed in Study I. 
ECs were cultured into confluent monolayers on detachable cell culture inserts to a 
cell density of 2x105 cells/membrane.  The cells were then stimulated with AECAs 
positive and normal IgG solutions in order to assess the induced permeability of 
ECs in the presence of AECAs via electrophysiology-based Ussing Chamber 
System. This method estimates the epithelial electrical resistance (114). ECs 
membranes were detached from the inserts and mounted in chambers using Krebs 
buffer solution. The cultures were maintained at 37°C, oxygenated with 95% O2, 5% 
CO2, and stirred by gas flow. Green FITC-dextran of different molecular weights 
(4,000, 70,000 and 150,000 Sigma) was added to the lumen of the half-chamber. 
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Serosa samples of 0.2 ml were then collected at different time points during 2h and 
analyzed. The luminal to serosa permeability of the probes was measured by 
fluorescence at wavelengths of 480 and 535 nm for excitation and emission, 
respectively. All data sampling and pulse inductions were computer controlled 
using specially constructed hardware and software developed in LabView. 
Measurement of intracellular Ca2+ on endothelial cells (Paper I) 
Intracellular Ca2+ modulates numerous physiological cellular phenomena as an 
intracellular signaling molecule inducing cell proliferation, differentiation, migration 
and survival as well as triggering pathological events such as cell injury and death 
(115). For this reason, measurements of Ca2+ concentrations yield substantial 
insight into both normal and abnormal cell function. The principle of this method is 
that stimulated cells stained with fluorescents probes generate an excitation shift 
upon intracellular Ca2+ binding. However, this characterization technique is 
restricted because intracellular signaling pathways cannot be identified.  In Study I, 
intracellular measurements of Ca2+ were recorded in kidney and umbilical ECs after 
stimulation with different AECAs IgG fractions from CKD patients.  
Calcium flux is a primary feature of cell activity. The ability of IgG to mobilize 
Calcium flux was carried out as described in (116). Cultured HKECs and HUVECs 
cells were incubated with the fluorescent indicator Fura 2-AM (Calbiochem, La Jolla, 
CA) and the surfactant Pluronic F-127 (Sigma- Aldrich, Sweden) in HBSS solution 
(saline solution) with HEPES buffer for 30 min at 37°C and the ratio of fluorescence 
between 340 and 380 nm was recorded with commercially available software 
(Miracal, Life Science Resources). After 10 s of recording, 50 ml of IgG from ESRD 
patients with or without AECAs or normal IgG were added to the cells in different 
concentrations. The total recording time was 200s. 
ELISA (Enzyme-linked immunosorbent assay) (Paper III) 
ELISA is a qualitative or quantitative method to measure concentrations of a 
particular antigen (e.g. proteins, peptides, hormones or antibodies) present in a 
given fluid sample. ELISA begins by fixing an antibody to a plate. Next, non-specific 
analytes are blocked and the sample to be analyzed is applied to the plate. If the 
sample contains antigens corresponding to the fixed antibody binding will occur. 
Then, the sample is washed to remove all unbound components from the substrate. 
Then a secondary antibody which is coupled to a flouro or chromophore-containing 
enzyme is applied which will only bind to the antigens (if any) remaining from the 
sample.  Finally, a substrate is added allowing the linked enzymes to demonstrate a 
chromographic or flourescent signal (117). ELISA is a useful technique because it is 
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quick, simple to carry out, and relatively economical when working with uniform cell 
populations or multiple samples. Although ELISA provides information on the 
presence of a given analyte, it lends no information on its biochemical properties 
such as molecular weight or its spatial distribution in a tissue. Furthermore, the 
immobilization or fixation of cells might mask true antigens making them 
undetectable or giving false positive results (118). 
Detection for anti-vimentin IgG antibodies (Paper III) 
Vimentin is a cytoskeletal intermediate filament exhibited in many type of cells 
including ECs.  In transplantation, antibodies to this protein are grouped along with 
non-HLA antibodies. Anti-vimentin IgG antibodies in sera samples were semi 
quantified by ELISA. 
Creating a bioengineered-vein (Paper IV) 
Vein Decellularization 
Decellularization describes the process where cells are removed from an original 
tissue in order to maintain a natural matrix on which to create a new tissue. In this 
study, a 9 cm vein segment from a deceased organ donor (30 years) was washed 
and cleaned with distilled water and surfactant solutions containing antibacterial 
and antifungal agents to avoid microbial contamination. First, the vein was rinsed in 
distilled water for 72 h followed by incubation in detergent 1% triton X (for 3 h), 
extracting solvent 1% tri-n-butyl phosphate (for 3 h) and 4 mg/L deoxyribonuclease 
I, an enzyme to break residues of DNA (Sigma, Gothenburg, Sweden) in 1 M sodium 
chloride (for 3 h). One end of the graft was kept open while the other was clamped 
and the lumen was filled with 1% Triton X. The other end was then clamped and 
placed on an agitator at 37°C for 3 h with gentle shaking. At the end of the 
incubation time, one end of the specimen was opened, the contents of the lumen 
were emptied and the specimen was washed with phosphate buffered saline. The 
procedure was followed for treatment with tri-n-butyl phosphate and DNAse. Finally, 
the specimen was washed with distilled water overnight to remove cell debris. 
Seven cycles were run from triton to water. At the end of the decellularization 
process, the graft was washed continuously for 48 h with PBS, which was changed 
every 6 h. 
Recellularization of a new vein 
After decellularization, endothelial and smooth muscle cells (around 
7·5?104cell/cm2) differentiated from the patient’s bone marrow cells were seeded in 
the new clean matrix. First, one end of the graft was clamped and endothelial cells 
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were applied longitudinally to the internal surface of the matrix with a micro syringe. 
Then, the open end was clamped and the matrix was placed on a laboratory shaker 
system (Rock n Roller Mixer 820, Boule Medical, Stockholm, Sweden) at 37°C with 
5% CO2. After 3 days, the internal surface was seeded with smooth muscle cells 
suspended for 3 days. The matrix was then placed within a bioreactor. Endothelial 
serum-free medium was added internally (25 mL) and serum-free smooth muscle 
cell differentiation medium externally (25 mL) then rotation started at 1.5 revolutions 
per min (at 37°C with 5% CO2). The external and internal medium was changed 
every 72 h. The extracted medium was tested for microbial colonization with a 
commercially available kit (Invitrogen, Sweden, category number C-7028). The 
bioreactor culture lasted 2 weeks in total. 
Histology (Paper I - IV) 
Histology is a technique that is commonly used to examine and diagnose tissues 
and cells microscopically by staining samples with different antibody markers.  In 
cell cultures or cell suspensions, it is called immunocytochemistry and in tissues, 
immunohistochemistry (119).  Once tissues are removed from the body, they 
undergo a process of autolysis, which is initiated soon after cell death by the action 
of intracellular enzymes causing the breakdown of protein and eventual liquefaction 
of the cell (120).  The main objective with the histology is to preserve cells and 
tissue constituents in as close a life-like state as possible and to allow them to 
undergo further preparative procedures without change. Different methods have 
been developed and different settings are used in the laboratories depending of the 
tissue/cells and characteristics of the antibodies used. In this work, 
immunofluorescence and immunohistochemistry staining were used according to 
local standard procedures. 
Immunocytochemistry (Paper I and IV) 
In Paper I immunofluorescence staining of adherens and tight junction proteins on 
HKECs was performed. 3x105 HKECs were grown on eight-chamber cell culture 
slides and then stimulated with either AECAs-positive IgG fractions from ESRD 
patients or healthy controls overnight. After washing these cells, primary antibodies 
to vascular endothelial cadherin (VE-cadherin, BD Pharmigen) and tight junction 
proteins ZO-1, Claudin-1 and Ocludin-1 (Zymed Laboratories, San Francisco, CA) 
were stained on HKECs using secondary fluorescent antibodies CY3 goat anti-
mouse (Jackson ImmunoResearch) and Alexa Fluor 488 donkey anti-mouse 
(Invitrogen). Nuclei staining with DAPI were also included. Specimens were then 
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mounted and dried for microscopic analysis under a confocal fluorescence 
microscope. 
Staining of actin filaments was also applied on monolayers of HKECs, which were 
grown and stimulated with different IgG fractions from AECAs positive, negative and 
normal. Then, these HKECs monolayers were fixed with formaldehyde and 
permeabilized with Triton X-100 for staining of actin filaments with FITC-conjugated 
phalloidin (Sigma-Aldrich Sweden). After additional washes, the HKECs were 
viewed in a fluorescence microscope. 
In Paper IV differentiated endothelial cells from bone marrow of the patient were 
stained, with dual-colour immunofluorescence for vascular endothelial cadherin, 
acetylated LDL, and von Willebrand factor, and counterstained with DAPI to confirm 
the endothelial phenotype. In the same way, smooth muscle cells were stained with 
?-actin and vimentin to confirm the smooth muscle cell phenotype. 
Immunohistochemistry (Paper I – IV) 
Paper I  
Paraffin-embedded kidney biopsy sections from normal individuals and ESRD 
patients were incubated with sera AECA-positive, negative and normal and stained 
with the same panel of adherens and tight junction antibodies used in 
immunocytochemistry; claudine-1 and ocludin-1 by biotin-peroxidase complex and 
VE-cadherin and ZO-1 by proteinase K method. 
Paper II  
Paraffin-embedded cardiac biopsies sections from a twice-heart-transplanted 
patient were analyzed for cellular and antibody mediated-rejection with CD68 
(monocyte/macrophage marker) and C4d (an AMR marker) antibodies, under 
protocols from the department of pathology at Sahlgrenska Hospital. 
Paper III  
Immunofluorescence deposition of IgG and IgM on capillary endothelium in heart 
frozen sections from transplanted patients with and without rejection episodes were 
analyzed. Consecutive biopsy sections were stained with endothelial adhesion anti-
human CD31 (Sino Biological Inc., Beijing, China) and incubated at 4°C overnight. 
On the following day, goat anti-mouse Alexa fluor 594 (Invitrogen, Stockholm, 
Sweden), goat anti-human IgG and IgM (Jackson ImmunoResearch Laboratories 
West Grove, PA, USA) secondary antibodies were added and incubated. After three 
washing steps with cold PBS, blue fluorescent nuclei stain with DAPI was performed 
and specimens were mounted and dried for microscopy analysis. Immunoglobulin 
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deposition was quantified with a specific protocol, established by the Centre for 
Cellular Imagining (core facility) at Gothenburg University. 
 
Paper IV  
After each decellularization cycle of the vein, a small piece of tissue was also 
screened for the presence of nuclei (DAPI staining), HLA class I, and II antigens, 
and was verified histologically with standard procedures (121).  
Statistics 
Paper I  
All values are expressed as means SD (standard deviation) unless otherwise 
indicated. A P value <0.05 was considered significant. Differences among groups 
were analyzed by ANOVA using a Kruskal-Wallis test. The statistical analysis was 
performed using SAS software (version 9.1.3, SAS, Cary, NC). Relative changes in 
electrical resistance as well as cumulative permeability of probes were performed 
by Student’s T-test for paired and unpaired values using SPSS software (SPSS, 
Chicago, IL). 
Paper III  
Data is presented as mean SD for continuous variables and number of subjects. 
Percentages are used for categorical variables. Fisher’s two-sided exact test was 
used for the comparison of categorical variables. In calculations comparing 
presence of AECAs in serum and respective EMB outcome, generalized estimating 
equations (GEE) were used. Differences between EMB images from AECAs positive 
patients and AECAs negative (controls) were analyzed using Mann-Whitney-U test. 
A probability value of p? 0.05 was considered to indicate statistical significance. 
Ethical permits 
The consent obtained from each individual and all the protocols for the studies were 
approved by the different Ethics Committees of the Karolinska University Hospital 
Huddinge in Stockholm (Paper I) and the Sahlgrenska University Hospital in 
Gothenburg, Sweden (Papers II, III and IV).  
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REVIEW OF RESULTS  
Tables and Figures of each study are only mentioned in the text. To facilitate 
interpretation of the results, please refer to respective paper. 
AECAs in ESRD patients (Paper I) 
Characterization of ECs from kidney  
Investigations for detection of endothelial injury caused by AECAs have traditionally 
used ECs from easily access tissue from large vessels such as umbilical cord, 
which may be not clinically relevant. Herein, tissue-specific ECs lines of HUVECs 
were used as a control, and HKECs were used to target specific AECAs in ESRD 
patients. The isolated HKECs displayed their characteristic cobblestone morphology 
in culture and a tubular network formation in Matrigel. Electron microscopy revealed 
the presence of fenestrae and phenotypic expression of various endothelial 
markers, which are distinctive features of glomerular ECs.  
AECAs IgG fractions bind to tissue-specific ECs from the kidney  
Among the 45 ESDR patients in the study, more than half of them had positive flow 
cytometric AECAs that bound to HKECs (P<0,0001) and not to HUVECs (56% vs 
4%) compared to controls (Table 3). Furthermore, to confirm the retention capacity 
of binding in these antibodies, IgG fractions from the sera of patients with AECAs 
were isolated and tested against different ECs including aortic and lung. Once 
again, a strongly binding capacity was found only to HKECs (Figure 1E). These 
results allowed for the discrimination of a pool of kidney-reactive sera samples 
specific to AECAs positive and negative cases. The presence of AECAs was 
associated with females, systolic blood pressure, and peripheral TNF-? but not with 
any other clinical parameter. 
AECAs IgG fractions induce alterations on HKEC 
In order to investigate the effect of AECAs on HKECs permeability, in vitro staining 
with structural and cytoskeletal proteins on HKECs and HUVECs were performed in 
conjunction with penetrability assays. In culture, monolayers of HKECs stimulated 
with IgG fractions from AECAs positive patients demonstrated a decreased 
expression of tight junctions ZO-1 and Claudin-1 and adherens VE-cadherin 
proteins. Identical treatments to AECAs negative, AECAs normal and HUVECs cells 
showed no such effect (Figure 2 and 5A). A similar pattern was observed on kidney 
biopsies from patients with AECAs. In these patients, tight and adherens junction 
proteins were almost absent. This is in contrast to normal tissues, which generally 
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maintain the expression of tight junctions ZO-1 and occludin along tubular and 
glomerular regions.  Normal tissues also exhibit Claudin-1 around the periphery of 
glomeruli and VE-cadherin in capillary and other vessel areas (Figure 6). 
Furthermore, these antibody fractions were also able to phosphorylate VE-cadherin, 
an endothelial adherent protein associated to vascular permeability (Figure 5B).  
A comparable reactive influence was seen in HKECs treated with AECAs positive. 
Upon binding, these antibodies triggered the activation of HKECs as detected by a 
rapid calcium flux response and an increase in the number and density of F-actin 
stress fibers (Figure 4). Macromolecular flux and electrical resistance 
measurements were taken via the diffusion of different FITC-dextrans and the 
electrical resistance of monolayers of ECs stimulated with IgG positive fractions and 
IgGs from controls. AECAs positive facilitated a significant passage of dextrans and 
a correlated decrease in the measured electrical resistance (P=0.002). This 
demonstrates the permeability of the kidney endothelial cell barrier is affected 
negatively when AECAs are present (Figure 3).  
 
Successful heart retransplantation with endothelial cell AMR (Paper II) 
First transplant - clinical facts 
Prior transplantation, the patient had no HLA antibodies and the crossmatch test for 
donor T and B cells was negative. After his first transplant, the patient received 
induction therapy with different immunosuppressant and corticosteroid medications 
(a detailed regimen is described in the paper). However, his status deteriorated 
progressively within the first month showing clinical signs of rejection as 
corroborated on his EMB. For this reason, he was accepted for urgent 
retransplantation. In conjunction with treatment, an analysis on autologous AECAs 
and donor AECAs was performed. Before first transplantation, both tests were 
negative for the presence of AECAs. During the second week following his 
operation, the patient presented a mild cellular rejection (ISHLT-1R), and negative 
Cd4 deposition. Additionally, tests for donor AECAs (type IgM) returned a positive 
result, and test results for autologous AECAs were negative. After three weeks, he 
showed severe macrophage infiltration (CD68+), diffuse eosinophilic and 
lymphocytic infiltration, and negative C4d. Tests for both donor AECAs IgM and 
autoreactive AECAs IgG and IgM were positive. During the next several days, the 
patient started to develop cardiogenic shock. Extracorporeal membrane oxygen 
was initiated and later he was put on a biventricular assist device (BVAD). His EMB 
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showed myocyte necrosis, severe antibody, cellular-mediated rejection (ISHLT-3R, 
AMR) and C4d capillary deposits (Figure 2A). At this point, a severe AMR caused 
by non-HLA AECAs was assumed, and an AMR protocol consisting of 
plasmapheresis, intravenous immunoglobulin and rituximab was initiated.  
Second transplant - clinical facts 
Due to his poor prognosis, the patient was accepted for urgent retransplantation 
and a donor organ was available within 1 day. Lymphocytic crossmatch tests and 
tests for donor and autoreactive AECAs were negative. One week after 
retransplanation, his EMB showed normal myocardium, negative C4d, low 
lymphocytic infiltration, a slightly increased amount of macrophages (CD68+, Figure 
2B) and negative donor and autologous AECAs. Although the patient was clinically 
stable, extended plasmapheresis treatment and immunosuppressive therapy were 
administered. During the next weeks, patient’s EMB showed regression of 
macrophage infiltration along with C4d deposition. Tests for donor and auto AECAs 
were also negative. One month after retransplantation, his EMB showed antibody 
cellular rejection (ISHLT-2R), but no AMR. Seven weeks after, a normal myocardium, 
without macrophages (ISHLT-0R) and negative C4d were seen in his EMB. Thirteen 
weeks after the first transplantation, the patient was discharged home. Thirty months 
later, the patient is still doing well. A summary of all the major events is shown in 
Figure 1 of this paper.  
 
Relevance of de Novo allo and auto reactive AECAs in heart-transplanted 
patients (Paper III) 
EPC/Tie-2 cells isolated from PBMCs  
EPC/Tie-2 cells from donors and patients were isolated from frozen PBMCs by flow 
cytometry with the EPC-XM kit.  Two major cell populations were displayed, 
lymphocytes and monocytes-granulocytes. The monocyte region was tested for 
AECAs. PBMCs viability at the time of EPC/Tie-2 isolation for both donor and 
patients ranged between 70-95% with a Tie-2 yield of 1,2±4x106 cell/25-50 mL blood 
and 1,9±7x106 cells, respectively. 
Donor and autologous AECAs  
All the patients were transplanted in the absence of DSA HLA prior transplantation. 
They also had negative standard lymphocytic crossmatch test, negative 
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lymphocytic EPC-XM and negative autologous AECAs. However, three patients 
presented positive donor AECAs. A significant association between the use of a 
ventricular assist device (VAD) and the presence of IgG AECAs was found 
(P=0.027). 
Donor AECAs vs. rejection events  
Post transplantation eight out of 14 patients had donor AECAs (four with IgG AECAs, 
one with IgM and three with both) and all the available sera samples after 
transplantation were correlated with their respective EMB outcome (ISHLT 0R-3R). 
Among 42 samples, 10 had positive IgM AECAs and six were associated to ongoing 
rejection episodes (P=0.012, ISHLT-1R-3R) (Figure 2A, Table 3 of this paper). Most 
of the patients with IgG AECAs (12/42) had no rejections. Meanwhile, nearly half of 
the patients with IgM AECAs demonstrated mild (1R) to moderate (2R) rejections. 
Autoreactive AECAs vs. rejection events 
Autologous IgM AECAs were positive in four patients. Their sera samples were 
significantly associated with verified allograft rejection in EMB (P=0,008 Figure 3). 
Three patients were positive for autologous AECAs with ongoing rejection and two 
tested positive for donor AECAs. Furthermore, one patient had positive autologous 
and donor AECAs but no ongoing rejection.  
AECAs detected with EPC-XM vs. cardiac microvascular ECs  
To confirm that the AECAs detected by EPC-XM test were also reactive to tissue-
specific EC, flow cytometry was performed to assess their binding capacity to 
HCMECs.  5/14 patients had positive AECAs against HCMECs. These patients were 
also positive AECAs reactive by the EPC-XM test. 
AECAs detected with EPC-XM vs. other non-HLA antibodies 
Rejections and organ failure have also been associated to two other important non-
HLA antigenic determinants called MICA and vimentin. Screenings of these proteins 
showed that only one patient was AECAs and anti-vimentin positive. None of the 
patients had anti-MICA antibodies. 
Deposition of IgG/IgM on EMB 
Given the correlation between the presence of donor and auto AECAs (type IgM) 
with rejection episodes, deposition tests of IgG and IgM in the capillary endothelium 
were performed on the EMB of patients with and without AECAs. Tests indicated 
that there was no significant difference in the distribution of IgG in patients with and 
without AECAs. On the contrary, the tests of the distribution of IgM in the biopsies of 
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patients with AECAs were markedly higher when compared with controls (P=0.0001) 
(Figure 4).  
AECAs in a bioengineered-transplanted vein (Paper IV) 
A patient diagnosed with splenomegaly, portal hypertension and advanced 
extrahepatic portal vein obstruction was accepted for a Meso-Rex bypass 
procedure with an autologous stem cell derived vein graft as a rescue alternative.  
The new created vein graft  
The donor's iliac vein was biopsied for histological staining. The tests revealed an 
intact nucleated tissue with a defined endothelial layer expressing HLA-I but not 
HLA-II since ECs and smooth muscle cells do not express these antigens 
constitutively. During seven cycles of decellularization, a translucent tissue was 
obtained. This tissue showed the architecture of an acellular preserved matrix and 
did not contain HLA-I or HLA-II, Figure 3A. The patient's CD133-bone-marrow-
derived-positive cells were successfully grown and differentiated into mature 
endothelial and smooth muscle cells. These differentiated cells were then taken to 
recellularize a new blood vessel in a bioreactor over the course of two weeks. 
Phenotypic endothelial characterization was confirmed by the positive IF expression 
of VE-cadherin, acetylated-low density lipoprotein and positive von Willebrand 
factor. Positive tests for ?-smooth actin and vimentin denoted the distinctive line of 
smooth muscle cells (Figure 4). Tissue sections of the newly recellularized vessel 
displayed a widespread re-endothelialization to the lumen and valves of the vein, 
and a homogeneous smooth muscle attachment in the tunica media (Figure 5). All 
tests for autologous and alloreactive AECAs prior to the surgical procedure were 
negative.  
Transplantation of the bioengineered-graft 
A section with suitable length of the new vein was placed in cold storage solution 
immediately before surgery. An illustrative image of the surgical correction is shown 
in Image 3. 
 
46
 
Image 3. Surgical replacement of the new blood vessel with autologous stem cells 
Once the graft was implanted, blood flow was measured presenting normal flow 
rates of 25–30 cm/s in the portal vein and 40 cm/s in the artery. One week after 
surgery, the vein graft was visualized by computed tomography (CT) angiography. 
The vein exhibited good attachment around the surrounded vasculature (Image 3). 
During the first six months of recovery the patient received daily doses of 75 mg of 
aspirin, and 10 mg omeprazole. No immunosuppressive medication was 
administered, and the patient's routine laboratory tests were normal. However, nine 
months into recovery, the patient had a decreased platelet count low blood flow 
from the portal artery, and a reduced lumen in the implanted vein (8 mm to 4–6 mm). 
At one-year follow-up, a CT angiography showed a narrowed lumen. To correct the 
defect of the graft, a second operation was undertaken. Two alternatives were 
considered. First was the transplantation of an autologous vein from the left internal 
jugular, and second was the creation of a new graft using the patient's stem cells. 
Intra-operatively, the affected graft showed a compressed segment with a blocked 
passage of blood through the mesocolon, and the affected vein graft was replaced, 
using a new bioengineered-vein. The alternative use of internal jugular vein was 
discarded because they were too short. After surgery, blood flow in the new graft 
and intrahepatic portal vein was restored (Figure 2). The patient was put on 
intravenous heparin for two weeks and was prescribed anticoagulants for almost a 
year. Despite two surgical procedures, the quality of life of the patient showed an 
evident physical and mental improvement manifested in increased height, weight, 
physical activity and power of concentration during school activities along with 
improvement in her speech articulation.
Follow-up measurements for AECAs were taken at one, three, six, nine, and 12 
months. AECAs tests taken after the first transplant were negative for AECAs. 
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However, autologous AECAs IgM started to appear with slightly positive fluctuations 
during the first six months after the second transplantation as indicated in (Image 4).  
 
 
Image 4. Flow cytometric histograms showing negative controls (grey) and positive controls along with 
patient’s sera samples AECAs (green) 
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GENERAL DISCUSSION 
In paper I, the obtained results suggest that AECAs alter the expression of important 
tight and adherens proteins that maintain the renal microvascular permeability. By 
working with in vitro monolayers of cultivated HKECs and within vivo kidney 
biopsies, a decreased expression of regulator permeability proteins, tight junctions 
(ZO-1), Claudin-1 and adherens (VE-cadherin) were observed upon stimulation with 
immunoreactive AECAs. The main function of tight and adherens junction proteins is 
to seal adjacent cells thus providing a strong mechanical attachment (122). 
However, they also serve to regulate the passage of molecules and ions trough the 
space between cells (123). In some animal models, it has been demonstrated that 
the expression of specific claudins can alter transepithelial electrical resistance and 
charge selectivity (124-126). 
In HKEC-monolayers stimulated with AECAs, the diffusion of enhanced dextran, the 
falling of endothelial electrical resistance and the rapid mobilization of cytosolic 
Ca2+, may indicate a reorganization of cytoskeletal actin filaments, essential for 
changes in cell shape and formation of F-actin (127). Endothelial cell permeability 
has been associated with calcium-dependent conformational changes in the 
endothelial cell cytoskeleton, leading to cell contraction and intercellular gap 
formation (116, 128). It was showed that stimulation of HKECs through AECAs 
activation resulted in loss of peripheral actin bands and increased stress fiber 
density, which in turn, is a sign of membrane disturbance and loss of endothelial 
permeability. 
Many pathologic processes target junctional proteins, resulting in the disassembly 
of junctions and breakdown of tissue integrity (129). Reactive AECAs also induced 
phosphorylation of VE-cadherin, an almost exclusive endothelial adherent protein in 
endothelial cells and reported as regulatory of vascular permeability (130, 131). This 
demonstrates that these antibodies might have some specific functional effects on 
kidney endothelial cells.  
Cytokines and ischemic injury has been regarded to endothelial dysfunction where 
they increase permeability, and intercellular gap formation (15, 132, 133). In vitro 
studies have shown how the permeability of kidney, umbilical epithelial cells/ECs 
and liver sinusoidal ECs may be provoked or impeded transcellularly through the 
formation of caveolae and fenestrations (134, 135). However, the mechanisms that 
interrupt the endothelial regulatory balance within the kidney microvascular bed are 
still not understood.  
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Kidney endothelial dysfunction in ESRD patients is recognized as a critical risk 
factor for atherosclerotic CVD (136). Since CVD is a manifestation of vascular 
dysfunction, it is valid to assume that biological alterations are occurring within the 
kidney endothelium in CKD patients. In general, ESRD patients represent a group 
with severe disease and it is possible that the correlation between increased levels 
of AECAs reactive with specific HKECs is an epiphenomenon. However, damage to 
the ECs during the progression of ESRD might lead to the exposure of antigens, 
which engender the development of AECAs. Therefore, it is more reasonable to 
hypothesize that these antibodies possess functional properties, which induce 
alterations contributing to the impairment of the kidney glomerular barrier. 
In paper II a clinical case of endothelial cell AMR and successful treatment in a 
heart-transplanted patient was presented. Traditionally, AMR is relatively minor 
compared to cellular-mediated rejection in heart transplantation (137).  However, 
cases of hyper and acute rejection due the presence of HLA antibodies have been 
reported (138, 139). Study II is unique insofar as the patient was monitored to 
control the prevalence of AECAs in parallel with regular clinical assessments. 
By monitoring presence of donor-specific AECAs type IgM post-transplant, during 
cardiac rejection, and graft failure, it was possible to implement an adequate 
regiment of desensitization making the patient eligible for retransplantation. Thus, 
this study suggests that in heart-transplanted patients, early heart failure might be 
avoidable if negative HLA and positive AECAs are observed shortly after 
transplantation.   
In paper III, preliminary data about the prevalence of de novo allo and autologous 
AECAs was presented in association with early rejection events by testing 
sequential sera samples pre- and post-transplantation within six months follow-up. 
As in paper II, the new EPC-XM assay and cardiac microvascular ECs to detect 
AECAs was used. 
The significant correlation found between the presence of AECAs prior to 
transplantation and the use of VAD was not surprising. VAD is often necessary to 
maintain circulation in patients with heart failure and its use has been related with 
the development of HLA antibodies (140-142). It is also likely that VAD might induce 
an immune response leading to the formation of AECAs.  
Good HLA matches do not guarantee rejection-free transplantation. Apart of AECAs, 
the presence of other non-HLA antibodies such as the MICA (MHC class I–related 
chain A) has been associated with an increased frequency of graft loss, especially 
in kidney transplants (143, 144). However, these antibodies are also present in heart 
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transplants (145) but in the group of our heart-transplanted patients, none of the 
individuals had these antibodies. Similar results were seen for anti-vimentin 
antibodies, where only one patient had anti-vimentin positive reaction. This fact 
suggests that in heart-transplantation, AECAs are clinically relevant (146).  
Many of the donor and/or autologous AECAs positive patients suffered from 
inflammatory disease (29%) and other non-related pathologies to inflammation 
(36%). In paper II, the retransplanted patient also had ulcerative colitis and in this 
study, three patients that had autoreactive AECAs also had autoimmune diseases 
as well, giving the possibility that AECAs were a triggering cause. Nevertheless, 
autoantibodies in most cases appear to represent de novo autoantibody 
development rather than recurrence of preexisting autoimmune condition (147-150).  
Furthermore, the sera samples from patients tested positive for AECAs by the EPC-
XM kit, were also tested against cardiac microvascular ECs showing comparable 
results. This indicates that the EPC-XM kit can be clinically reliable test for AECAs. 
In paper IV the successful transplantation of a bioengineered blood vessel was 
reported. An acellular human blood vessel was recellularized with autologous stem 
cells. Using a bypass procedure, this technology might serve as an alternative 
treatment for patients suffering venous insufficiency, obstructed veins or inadequate 
autologous veins without the need of an immunosuppressive regimen. 
In the transplantation scenario, the shortage of organs is a reality (151). 
Advancements in tissue engineering utilizing natural or artificial tissue scaffolds 
repopulated with stem cells may be a viable alternative to contemporary techniques. 
The vein graft in Study IV was recellularized with autologous stem cells and tissue 
rejection after transplantation was not expected. The patient was closely monitored 
for more than a year for the presence of HLA and AECAs antibodies. Donor HLA 
and AECAs were not present. Although, the patient tested marginally positive for 
AECAs IgM after his second transplantation, it is premature to suppose that their 
presence was directly related to the procedure. It might believe that these 
antibodies developed as a result other phenomena.  
In general, IgM are usually considered as irrelevant natural autoantibodies (152). 
However in organ transplantation, they can be directed against HLA. It has been 
found HLA IgM antibodies against donor HLA antigens before transplantation and 
after both early and late post-transplant course (153, 154). Nonetheless, the effect of 
the IgM antibodies is still a matter of debate. Some authors show that they have a 
protective effect on the graft, but other reports show that they can negatively 
influence graft outcome (155-157). 
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Representation of possible mechanisms by which AECAs included in this thesis 
might contribute in endothelial dysfunction. 
 
 
Image 5. Possible mechanisms of endothelial dysfunction mediated by anti-endothelial cell antibodies. 
 
1. AECAs IgG/IgM bind endothelial cell antigens and may activate complement (C’) leading 
to cytotoxicity. Alternatively: 2. AECA-antigen complex are taken up by antigen presenting 
cells via complement or Fc receptors and proinflammatory events are initiated, where 
signaling processes within the microvascular endothelium stimulate the secretion of 
cytokines, chemokines and generate the activation of different surface endothelial adhesion 
molecules such as VCAM-1, ICAM-1 and E- and P-selectines. In parallel, upregulation of 
tissue factor and other clotting agents as trombodulin, trigger a procoagulative activity. 
Apoptosis and cell shrinkage may also be initiated by disrupting tight and adherens junction 
proteins (Claudin, ZO-1 and Ve-cadherin) on kidney microvascular endothelial cells leading 
to a “leaky” endothelium. Cytokines/Chemokines production attracts the migration of 
inflammatory cells (NK cells, lymphocytes, monocytes and macrophages) to the 
endothelium leading to enhanced cell-mediated immunity. 3. As immature monocytes enter 
the tissue, they become macrophages which modulate activation of T cells by secreting 
more cytokines/chemokines leading to adaptive immune responses.  AECA may also bind 
antigens on the endothelium via Fc receptors leading to activation of NK cells and antibody-
dependent cell-mediated cytotoxicity (ADCC). As result of all this cascade of events, 
AECAs may amplify inflammatory responses or cause microvascular damage leading to 
pathological changes resulting in organ disorders or allograft rejections. 
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Important considerations about AECAs results 
It is important to take into account that additional microvascular ECs lines must be 
investigated in conjunction with AECAs and CKD. In these studies, ECs from a 
single donor were used. It would be informative to see how AECAs react to other 
human glomerular ECs lines.    
In heart-transplanted patients, donor-specific and autologous AECAs of the non-
HLA type detected post-transplant were significantly associated with cardiac 
allograft rejections. Even though the sample size of this study was small, the results 
were preliminary in essence. Further work will take into account a larger number of 
patients in order to improve the statistics of these findings. Furthermore, it is 
necessary to gather more data from heart-transplanted patients to establish reliable 
cutoff points for the detection of positive donor and autologous AECAs by the EPC-
XM kit. In studies II and III, the criteria for a positive AECA reaction against donor 
were the same used in the only kidney multicenter EPC-XM study by Breimer et al, 
2009, where a shift of more than or equal to 50 and 80 channels for IgG and IgM 
respectively above the negative control serum was considered positive (106). Given 
that the EPC-XM system is relatively new, it is still necessary to evaluate its efficacy 
in a clinical setting for heart-transplanted patients.  
Comparably, to consider positive autologous AECAs by flow cytometry in 
bioengineered vein grafts, consistent cutoff points have to be determined by using 
proper control groups.  Based on a set of 20 healthy individuals (the same as in 
paper II and III), autoantibodies IgM were established where a shift of more than 52 
channels, was assumed as significant. The presented data is from one patient, 
which enormously limits the condition of our AECA report. However, it is important to 
mention that this kind of transplants with bioengineered veins has been carried out 
in two more children, and they are in focus for monitoring AECAs at our center. 
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CONCLUSIONS 
The studies covered under this thesis support the following conclusions: 
? The presence of AECAs is a critical problem in chronic kidney diseases and 
organ transplantation. 
? AECAs binding to glomerular endothelial cells are present in high prevalence 
in ESRD patients. These antibodies may cause dysfunction of renal 
endothelium leading to pathological changes of clinical relevance. 
? AECAs are present in heart-transplanted patients, especially in the absence 
of HLA-antibodies prior-transplantation. These antibodies may be associated 
with poor heart graft outcome. 
? The presence of donor and/or autologous AECAs detected by the EPC-XM 
test may increase the risk of early rejection events in heart-transplanted 
patients. 
? In transplants of autologous bioengineered tissues, autologous-reactive 
AECA may be produced. However, the exact significance of the presence of 
these antibodies in such transplants needs to be further studied. 
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PERSPECTIVES 
Endothelial dysfunction caused by AECAs is becoming increasingly recognized as 
critical in the pathogenesis of various organ disorders as well as acute and chronic 
organ allograft outcomes. Clinically important unknown AECA immune targets and 
the consecutive lack of detection methods currently make AECA mediated 
destruction particularly difficult to diagnose and treat.  
The existence of polymorphism or presence of antibodies with different specificities 
in the endothelial-reactive/specific antigenic systems justifies the need for detection 
and specificity determinations of non-HLA antibodies in organ transplantation. 
Continued efforts to define the AECA antigens using relevant or donor-specific 
endothelial cells as targets is absolutely essential to clarify the pathogenic 
mechanisms by which they contribute to rejection or other forms of tissue injury. 
Furthermore, the clinical importance of AECAs in organ transplants other than 
kidney has to be studied and established. The extension of EPC-XM studies pre- 
and post- transplantation of different organs will add important value to further 
improvement in donor organ selection and transplant outcome. A better recipient 
selection based on a negative lymphocyte and endothelial cell crossmatch may 
probably decrease the incidence of acute rejections and early graft loss in heart 
transplanted patients. 
In CKD patients, determining and quantifying the presence of AECAs at different 
stages of renal disease will elucidate the clinical prevalence of AECAs in this group 
of patients. 
Conclusively, to define the antigens recognized by AECAs will provide greater 
understanding of the nature of these antibodies, which can be potentially harmful. 
This will continue to be an area of importance in terms of fully understanding the role 
of AECAs as mediators of endothelial destruction in organ and cell transplantation 
as well as other disease with vascular involvement with the potential for clinical 
intervention.  
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